Please REGISTER to see our extended content offering and to become a member of our online community.
Our Profile
D&D Pharma is pioneering the development and successful application of phage-based therapeutic solutions. It is our vision to offer effective patients therapy options in indications with acute and growing medical need.
D&D Pharma develops medical products which address current acute medical and economic patient needs. This section aims at providing necessary information to D&D Pharma shareholders and investors.
During 2005, the 329 publicly held biotechnology companies in the United States earned $47.8 billion in combined revenue, with market capitalizations of $410 billion. Meanwhile, the 1,086 private U.S. biotech firms earned revenues of $2.9 billion. (Ernst & Young annual scorecard, New York Times, April 5, 2006)
The biotechnology industry employed 713,000 workers in 2002 and is anticipated to employ 814,000 workers in 2007 (Economy.com, Industry Workstation, Biotech industry forecast.
D&D Pharma is pioneering the development and successful application of phage-based therapeutic solutions. It is our vision to offer effective patients therapy options in indications with acute and growing medical need.
Company & Investors
